Table 2.
Comorbidity rates in the three groups.
| Comorbidities | MDD-r N = 2850 |
TRD N = 570 |
non-MDD N = 2850 |
P1 | P2 | P3 | P4 |
|---|---|---|---|---|---|---|---|
| Arterial hypertension, n (%) | 989 (34.70) | 207 (36.32) | 806 (28.28) | 0.006 | 0.231 | <0.001 | <0.001 |
| NIDDM, n (%) | 546 (19.16) | 112 (19.65) | 443 (15.54) | 0.048 | 0.394 | 0.011 | 0.058 |
| Ischemic heart disease, n (%) | 220 (7.72) | 47 (8.25) | 126 (4.42) | <0.001 | 0.337 | <0.001 | <0.001 |
| Chronic heart failure, n (%) | 105 (3.68) | 25 (4.39) | 63 (2.21) | <0.001 | 0.225 | <0.001 | <0.001 |
| COPD, n (%) | 248 (8.70) | 53 (9.30) | 130 (4.56) | <0.001 | 0.327 | <0.001 | <0.001 |
| Renal disease, n (%) | 80 (2.81) | 17 (2.98) | 52 (1.82) | 0.031 | 0.411 | 0.007 | 0.063 |
| Allergic diseases (pooled), n (%) | 585 (20.53) | 147 (25.79) | 427 (14.98) | <0.001 | 0.004 | <0.001 | <0.001 |
| Allergic rhinitis, n (%) | 209 (7.33) | 54 (9.47) | 172 (6.04) | 0.007 | 0.053 | 0.025 | 0.004 |
| Atopic dermatitis, n (%) | 28 (0.98) | 7 (1.23) | 22 (0.77) | 0.494 | 0.311 | 0.197 | 0.175 |
| Contact dermatitis, n (%) | 28 (0.98) | 10 (1.75) | 21 (0.74) | 0.068 | 0.091 | 0.157 | 0.038 |
| Asthma, n (%) | 320 (11.23) | 76 (13.33) | 212 (7.44) | <0.001 | 0.086 | <0.001 | <0.001 |
| Systemic autoimmune diseases (pooled), n (%) | 83 (2.91) | 27 (4.73) | 48 (1.68) | <0.001 | 0.026 | 0.001 | <0.001 |
| SLE, n (%) | 6 (0.21) | 2 (0.35) | 5 (0.18) | 0.701 | 0.296 | 0.381 | 0.249 |
| Rheumatoid arthritis, n (%) | 67 (2.35) | 21 (3.68) | 40 (1.40) | <0.001 | 0.056 | 0.004 | 0.003 |
| Sjogren disease, n (%) | 8 (0.28) | 2 (0.35) | 3 (0.11) | 0.253 | 0.396 | 0.064 | 0.168 |
| Systemic sclerosis, n (%) | 0 | 1 (0.18) | 0 | 0.091 | 0.158 | 0.5 | 0.158 |
| Polymyositis/dermatomyositis, n (%) | 2 (0.35) | 1 (0.18) | 0 | 0.165 | 0.281 | 0.078 | 0.158 |
| Organ specific autoimmune diseases (pooled), n (%) | 362 (12.70) | 85 (14.91) | 265 (9.29) | <0.001 | 0.086 | <0.001 | <0.001 |
| IDDM, n (%) | 19 (0.67) | 5 (0.88) | 8 (0.28) | 0.054 | 0.307 | 0.017 | 0.069 |
| Hashimoto's thyroiditis, n (%) | 23 (0.81) | 5 (0.88) | 18 (0.63) | 0.677 | 0.434 | 0.216 | 0.278 |
| Graves' disease, n (%) | 6 (0.21) | 3 (0.53) | 9 (0.32) | 0.405 | 0.158 | 0.219 | 0.256 |
| Celiac disease, n (%) | 12 (0.42) | 4 (0.70) | 8 (0.28) | 0.299 | 0.224 | 0.185 | 0.123 |
| Vitiligo, n (%) | 16 (0.56) | 3 (0.53) | 15 (0.53) | 0.982 | 0.458 | 0.428 | 0.5 |
| Alopecia areata, n (%) | 1 (0.04) | 0 | 2 (0.07) | 0.716 | 0.158 | 0.281 | 0.079 |
| Pemphigus vulgaris, n (%) | 1 (0.04) | 0 | 1 (0.04) | 0.905 | 0.158 | 0.5 | 0.158 |
| Psoriasis, n (%) | 155 (5.44) | 37 (6.49) | 113 (3.96) | 0.007 | 0.178 | 0.005 | 0.011 |
| Chronic urticaria, n (%) | 31 (1.09) | 7 (1.23) | 26 (0.91) | 0.704 | 0.389 | 0.253 | 0.261 |
| Dermatitis herpetiformis, n (%) | 3 (0.11) | 0 | 4 (0.14) | 0.651 | 0.052 | 0.353 | 0.023 |
| Pernicious anemia, n (%) | 2 (0.07) | 0 | 1 (0.04) | 0.716 | 0.079 | 0.282 | 0.158 |
| Ulcerative colitis, n (%) | 17 (0.60) | 3 (0.53) | 13 (0.46) | 0.770 | 0.419 | 0.235 | 0.415 |
| Crohn's disease, n (%) | 36 (1.26) | 10 (1.75) | 21 (0.74) | 0.038 | 0.202 | 0.023 | 0.038 |
| Immune thrombocytopenic purpura, n (%) | 40 (1.40) | 7 (1.23) | 26 (0.91) | 0.221 | 0.365 | 0.042 | 0.261 |
MDD-r - Treatment Responsive Depression; TRD - Treatment Resistant Depression.
P1 – ANOVA, P2 – χ2 between MDD-r and TRD groups, P3 – χ2 between MDD-r and non-MDD groups, P4 – χ2 between TRD and non-MDD groups.